Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

abstract：:We have previously shown that all-trans retinoic acid (ATRA) increases the number of CFU-GM colonies grown from unseparated human bone marrow cells with crude sources of colony stimulating factors. In this study, we further characterized the effect of ATRA on the growth of CFU-GM stimulated by individual cytokines fro...

journal_title：Leukemia

authors： Douer D,Ramezani L,Parker J,Levine AM

更新日期：2000-05-01 00:00:00

abstract：:Recent studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple subclones. It is not known whether specific gene mutations typically occur in founding clones or subclones. We screened a panel of 94 candidate genes in a cohort of 157 patients with ...

journal_title：Leukemia

authors： Walter MJ,Shen D,Shao J,Ding L,White BS,Kandoth C,Miller CA,Niu B,McLellan MD,Dees ND,Fulton R,Elliot K,Heath S,Grillot M,Westervelt P,Link DC,DiPersio JF,Mardis E,Ley TJ,Wilson RK,Graubert TA

更新日期：2013-06-01 00:00:00

abstract：:The LH2 gene encodes a putative transcription factor containing two N-terminal LIM and one C-terminal HOX domains. The LH2 locus was mapped to 9q33-34.1, centromeric to the ABL gene. In a recent report, it was suggested that high levels of LH2 expression are consistently observed in chronic myeloid leukemia (CML) pati...

journal_title：Leukemia

authors： Al-Jehani F,Hochhaus A,Spencer A,Goldman JM,Melo JV

更新日期：1996-07-01 00:00:00

abstract：:A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor to detect aldehyde dehy...

journal_title：Leukemia

authors： Ratajczak J,Zuba-Surma E,Klich I,Liu R,Wysoczynski M,Greco N,Kucia M,Laughlin MJ,Ratajczak MZ

更新日期：2011-08-01 00:00:00

abstract：:A patient with the M2 subtype of AML who had a 45,X,-X,t(8;21) karyotype at diagnosis was found to have the Ph chromosome in one out of 37 evaluated cells 18 months after the initial diagnosis. Interphase FISH studies utilizing a BCR-ABL dual-color probe did not detect a fusion product 4 months prior to the appearance...

journal_title：Leukemia

authors： Najfeld V,Geller M,Troy K,Scalise A

更新日期：1998-04-01 00:00:00

abstract：:Inorganic arsenic trioxide (As(2)O(3)) is a highly effective treatment for acute promyelocytic leukemia (APL). However, other cancers do not respond well to this form of arsenic at clinically achievable doses. We tested a novel arsenical, S-dimethylarsino-glutathione (darinaparsin) for efficacy in various malignancies...

journal_title：Leukemia

authors： Diaz Z,Mann KK,Marcoux S,Kourelis M,Colombo M,Komarnitsky PB,Miller WH Jr

更新日期：2008-10-01 00:00:00

abstract：:The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

journal_title：Leukemia

authors： Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

更新日期：1996-05-01 00:00:00

abstract：:The tie receptor tyrosine kinase mRNA was originally identified as an amplified product in reverse transcription-polymerase chain reaction analysis of human K562 leukemia cell RNA. In situ hybridization analysis revealed that the corresponding mouse gene is expressed predominantly in endothelial cells. We have explore...

journal_title：Leukemia

authors： Armstrong E,Korhonen J,Silvennoinen O,Cleveland JL,Lieberman MA,Alitalo R

更新日期：1993-10-01 00:00:00

abstract：:Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...

journal_title：Leukemia

authors： Schiller GJ

更新日期：1998-09-01 00:00:00

abstract：:Interferon-alpha produces a complete hematologic and cytogenetic remission in approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we applied fluorescent in situ hybridization (FISH) methodology to examine the possibility that a low level of proliferating Philadelphia-chromosome-positi...

journal_title：Leukemia

authors： Zhao L,Kantarjian HM,Van Oort J,Cork A,Trujillo JM,Liang JC

更新日期：1993-02-01 00:00:00

abstract：:The response of human acute myelogenous leukemia (AML) cells to four different hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 beta (IL-1beta), interleukin-3 (IL-3), and stem cell factor (SCF)) and the relationship of the proliferative response of the AML cells to...

journal_title：Leukemia

authors： Tsuzuki M,Ezaki K,Maruyama F,Ino T,Kojima H,Okamoto M,Yamaguchi T,Nomura T,Miyazaki H,Wakita M,Matsui T,Hirano M

更新日期：1997-12-01 00:00:00

abstract：:Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment of CLL cells with Wnt5a causes Receptor tyosin kinase-like orpha...

journal_title：Leukemia

authors： Hasan MK,Rassenti L,Widhopf GF 2nd,Yu J,Kipps TJ

更新日期：2019-03-01 00:00:00

abstract：:Myeloperoxidase (MPO) is found in the azurophilic granules of normal myelocytic cells. Cytochemical staining for MPO activity is used clinically to distinguish myeloid from acute lymphoid leukemias (ALL). However, using a highly sensitive RT-PCR technique, it is possible to detect MPO mRNA in otherwise clear ALL. The ...

journal_title：Leukemia

authors： Serrano J,Román J,Jiménez A,Castillejo JA,Navarro JA,Sánchez J,García-Castellanos JM,Martín C,Maldonado J,Torres A

更新日期：1999-02-01 00:00:00

abstract：:A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

journal_title：Leukemia

authors： De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

更新日期：1989-04-01 00:00:00

abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

journal_title：Leukemia

authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

更新日期：1997-08-01 00:00:00

abstract：:East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

journal_title：Leukemia

authors： Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

更新日期：2020-10-19 00:00:00

abstract：:Expression of the human multidrug resistance 1 gene (MDR1), which encodes the P-glycoprotein transmembrane efflux pump, has been associated with treatment failure of some leukemias, primarily acute myeloid leukemia (AML). To elucidate the epigenetic events associated with overexpression of MDR1 in AML, we analyzed the...

journal_title：Leukemia

authors： Fryxell KB,McGee SB,Simoneaux DK,Willman CL,Cornwell MM

更新日期：1999-06-01 00:00:00

abstract：:Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

journal_title：Leukemia

authors： Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

更新日期：2019-09-01 00:00:00

abstract：:The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

journal_title：Leukemia

authors： Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

更新日期：1992-01-01 00:00:00

abstract：:Molecular rearrangements of Ph1 chromosome, the hallmark of CML, are clustered in a 5.8-kb DNA segment, the so-called breakpoint cluster region (bcr) of the phl gene that is localized to chromosome 22q11. In Ph1-positive (Ph1+) ALLs, the rearrangements have been shown to involve either the 5.8-kb bcr (called bcr+) or ...

journal_title：Leukemia

authors： Chen SJ,Chen Z,Grausz JD,Hillion J,d'Auriol L,Flandrin G,Larsen CJ,Berger R

更新日期：1988-10-01 00:00:00

abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

journal_title：Leukemia

authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

更新日期：2008-07-01 00:00:00

abstract：:Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of...

journal_title：Leukemia

authors： Moreira I,Papaioannou M,Mortuza FY,Gameiro P,Palmisano GL,Harrison CJ,Prentice HG,Mehta AB,Hoffbrand AV,Foroni L

更新日期：2001-10-01 00:00:00

abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

journal_title：Leukemia

authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

更新日期：2001-09-01 00:00:00

abstract：:Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma m...

journal_title：Leukemia

authors： Liesveld JL,Lancet JE,Rosell KE,Menon A,Lu C,McNair C,Abboud CN,Rosenblatt JD

更新日期：2003-09-01 00:00:00

abstract：:Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNalpha, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chr...

journal_title：Leukemia

authors： Russo D,Regazzi M,Sacchi S,Visani G,Lazzarino M,Avvisati G,Pelicci PG,Dastoli G,Grandi C,Iacona I,Candoni A,Grattoni R,Galieni P,Rupoli S,Liberati AM,Maiolo AT

更新日期：1998-04-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Leukemia

authors： Prutsch N,Gurnhofer E,Suske T,Liang HC,Schlederer M,Roos S,Wu LC,Simonitsch-Klupp I,Alvarez-Hernandez A,Kornauth C,Leone DA,Svinka J,Eferl R,Limberger T,Aufinger A,Shirsath N,Wolf P,Hielscher T,Sternberg C,Aberger F

更新日期：2020-11-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...

journal_title：Leukemia

authors： Van Bockstaele F,Pede V,Naessens E,Van Coppernolle S,Van Tendeloo V,Verhasselt B,Philippé J

更新日期：2008-02-01 00:00:00

abstract：:Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...

journal_title：Leukemia

authors： Fernández de Larrea C,Kyle RA,Durie BG,Ludwig H,Usmani S,Vesole DH,Hajek R,San Miguel JF,Sezer O,Sonneveld P,Kumar SK,Mahindra A,Comenzo R,Palumbo A,Mazumber A,Anderson KC,Richardson PG,Badros AZ,Caers J,Cavo M,Le

更新日期：2013-04-01 00:00:00

abstract：:Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

journal_title：Leukemia

authors： Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

更新日期：2019-06-01 00:00:00

abstract：:Children with acute lymphoblastic leukemia (ALL) with > or = 0.01% leukemic cells in the bone marrow after remission induction are at a greater risk of relapse. The most promising methods of detecting minimal residual disease (MRD) are flow cytometric identification of leukemia-associated immunophenotypes and polymera...

journal_title：Leukemia

authors： Neale GA,Coustan-Smith E,Pan Q,Chen X,Gruhn B,Stow P,Behm FG,Pui CH,Campana D

更新日期：1999-08-01 00:00:00